

### **REMARKS**

This paper is filed in Response to the Office Action mailed July 23, 2009. Claims 27 to 43 and 48 to 51 are pending. Claim 33 has been cancelled without prejudice. Applicants maintain the right to prosecute the cancelled claims in any related application claiming the benefit of priority of the subject application. Accordingly, upon entry of this paper, claims 27 to 32, 34 to 43 and 48 to 51 are under consideration.

#### **Regarding the Amendments to the Specification**

The specification has been amended to correct various informalities. In particular, the Figure Descriptions for Figures 1-7 at pages 19-22 have been renumbered to correspond to Figures 1-7. The specification has also been amended at page 1 to recite the related application information. The specification has also been amended at pages 8-9 to recite the amino acid positions of the amino acid sequence of SEQ ID NOs:1 and 3. Thus, as the amendments to the specification were made to address informalities, no new matter has been added and entry thereof is respectfully requested.

#### **Regarding the Claim Amendments**

The claim amendments are supported throughout the specification or were made to address informalities. In particular, the amendment to recite “light chain (V<sub>L</sub>) variable region sequence” and/or “heavy chain (V<sub>H</sub>) variable region sequence” was made to indicate that both light chain (V<sub>L</sub>) and heavy chain (V<sub>H</sub>) variable region sequences are present, and is supported, for example, at page 7, first and second paragraphs. The amendment to claim 31 is supported, for example, at page 8, first paragraph. The amendment to claim 43 to recite the amino acid positions corresponding to each of SEQ ID NOs:1 and 3 was made in response to the Examiner’s request, and is also supported, for example, by pages 2 and 4 of the sequence listing. Thus, as the claim amendments are supported by the specification or were made to address informalities no new matter has been added and entry thereof is respectfully requested.

#### **Regarding the Priority Claim**

This application is a national phase of International application no. PCT/DE2004/002503, in which inventorship was corrected to Heinz Peter Vollmers, as indicated by Form PCT/IB/306 issued during the international phase. This application was

filed listing an incorrect inventor, Philip Vollmers. A Petition to correct the inventorship of the application under 37 C.F.R. §1.48(a)(2), to list Heinz Peter Vollmers, instead of the erroneously named Philip Vollmers, was therefore filed on October 21, 2009. Accordingly, upon grant of the Petition by the Office of Petitions at the USPTO, inventorship of this application is in the name of Heinz Peter Vollmers, which therefore properly claims priority to International application no. PCT/DE2004/002503.

Regarding the Information Disclosure Statements

Applicants note that with respect to the IDS' filed November 17, 2008 and April 16, 2009, Applicants have resubmitted these IDS' in the requested format. Consideration of the listed references is respectfully requested.

The Examiner has also indicated that some of the German language references submitted in the IDS were not considered. Applicants respectfully submit that English language equivalents were submitted in an IDS for consideration. Applicants therefore respectfully request that the Examiner identify which references in the German language have not been considered.

Regarding the Objections to the Specification

The Examiner has indicated that the Figure Descriptions at page 19 of the specification do not appear to reflect the Figures filed with the application.

The specification has been amended to renumber the Figure Descriptions, which now correctly correspond to Figures 1-7. In view of the renumbering of the Figure Description, prior Figures 1 to 4 have been amended to recite pages of the sequence listing. In view of the amendments, the ground for objection is moot.

The Examiner has indicated that Figures 1 and 2 have no axis labels, and therefore allegedly interpretation of the data "impossible."

Applicants point out that in spite of the absence of axis labels, the data in Figures 1 and 2 is clear. In particular, in the paragraph bridging pages 19-20, the amended description states that "Figure 1 shows the measurement of oxLDL in dependence on the incubation time," and that "the amount of oxidized LDL increases with increasing incubation time." At page 20, second paragraph, the amended description states that "Figure 2 shows the proof of binding of SAM-6 to oxLDL," and that "the more LDL that is present in its oxidized form,

the more strongly the antibody SAM-6 according to the invention binds.” The x-axis of both corresponding Figures shows “0h,” “3h,” and “15h.” Thus, clearly the x-axis indicates the time point in hours, of LDL measurement. The y-axis of both corresponding Figures shows “0.2,” “0.4,” etc. Thus, clearly the y-axis indicates the amount of LDL measured. In view of the foregoing, the data shown in Figures 1 and 2 is clear.

The Examiner has indicated that the Specification does not reference the related priority applications.

The specification has been amended to recite the related application information. In view of the amendments, the ground for objection is moot.

The Examiner has indicated that pages 8-9 of the Specification do not refer to the amino acid positions of the amino acid sequence of SEQ ID NOs:1 and 3.

The specification has been amended to recite the amino acid positions of the amino acid sequence of SEQ ID NOs:1 and 3. In view of the amendments, the ground for objection is moot.

Regarding the Objection to Claim 43

The Examiner has indicated that claim 43 does not properly reference the amino acid positions of the sequences referenced in SEQ ID NOs:1 and 3.

Pursuant to the Examiner’s request, claim 43 has been amended to of recite the amino acid positions corresponding to each of SEQ ID NOs:1 and 3. Accordingly, the ground for the objection is moot.

I. REJECTION UNDER 35 U.S.C. §112, FIRST PARAGRAPH, ENABLEMENT

The rejection of claims 27 to 43 and 48 to 51 under 35 U.S.C. §112, first paragraph, as allegedly lacking enablement is respectfully traversed. The grounds for rejection are set forth in the Office Action, pages 5-15.

Claim 33 has been cancelled herein without prejudice. Thus, the rejection of claim 33 is moot and will be addressed with respect to amended elaims 27 to 32, 34 to 43 and 48 to 51. In regard to the amended claims, they require both the light (V<sub>L</sub>) and heavy (V<sub>H</sub>) chain variable region sequences (see, e.g., claims 27, 31 and 42). Thus, given that the claims require both light chain (V<sub>L</sub>) variable region and heavy chain (V<sub>H</sub>) variable region

sequences, all 6 CDRs are present. Accordingly, as both the light ( $V_L$ ) and heavy ( $V_H$ ) chain variable region sequences and all 6 CDRs are present the grounds for rejection at pages 8-11, and 13-14, are moot.

The proper standard for enablement under 35 U.S.C. §112, is whether one skilled in the art could make and use the invention without undue experimentation. In this regard, “a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed.” *In re Wands* 858 F.2d 731, 737 (Fed. Cir. 1988)

Here, claims 27 to 32, 34 to 43 and 48 to 51 are analogous to *Wands*, where the court held that screening hybridomas to determine those that produced monoclonal antibodies having a particular binding characteristic did not require undue experimentation. Likewise, undue experimentation would not be required to make and identify variant antibodies and fragments that bind LDL or oxLDL given that 1) producing antibody variants and fragments was routine in the art at the time of the invention; and 2) LDL and oxLDL routine binding assays are disclosed in the specification (e.g., pages 14-15) and other antibody binding assays were known in the art at the time of the invention. Consequently, there is no need for the skilled artisan to “predict” antibody variants or fragments that bind to LDL or oxLDL because making antibodies and fragments and identifying those that bind to LDL or oxLDL was routine at the time of the invention.

In regard to the statements in the Office Action (e.g., pages 7, 8, and 14) where allegedly one skilled in the art would not have been able to produce antibodies since they would have been unable to “predict which variation would not compromise antigen binding specificity,” or would encompass antibody embodiments having structures that are non-operative or “at least unpredictable as to their antigen affinity,” or “the ordinary artisan would have been required to identify candidate amino acids for substitution in the FR and/or CDR domains,” or “much less could one of ordinary skill in the art predict that any one or combination of all the FR and CDR amino acid substitutions .... would result in .... antibody clone having retained antigen binding activity,” Applicants respectfully point out that claims where no antibody has ever been produced are routinely granted by the Patent Office. Thus, if claims covering antibodies where no antibody has even been made and therefore where no antibody structure is known have been granted, surely knowledge of antibody structure or predicting the effects of particular variations on antibody binding is not required to satisfy the

enablement requirement under 35 U.S.C. §112. Consequently, it is clear that the standard for enablement under 35 U.S.C. §112 applied by the Patent Office to the claims is incorrect.

Furthermore, the Patent Office cannot insist that Applicants demonstrate enablement under 35 U.S.C. §112, first paragraph, by a particular methodology, namely predicting which antibody variants that would bind to LDL or oxLDL. In this regard, there is no authority requiring Applicant to demonstrate enablement by a particular methodology selected by the Patent Office to the exclusion of other methodologies. Consequently, the Patent Office cannot demand that Applicant demonstrate enablement by a particular methodology under 35 U.S.C. §112, first paragraph, since this would clearly be improper under 35 U.S.C. §112.

Here, the Examiner has tacitly acknowledged that the level of knowledge and skill with respect to antibody structure and function at the time of the invention was high. For example, as discussed at length in the Office Action the role of antibody heavy and light chain variable regions, particularly CDRs and FRs, in antigen binding was well understood by the skilled artisan at the time of the invention. The specification also discloses the role of antibody heavy and light chain variable regions, including CDRs in binding activity (page 8, second paragraph), and the predicted location and sequences of all CDRs in SEQ ID NOs:1 and 3 (see, pages 8-9, and Pages 1-4 of the Sequence Listing). Consequently, in view of the high level of knowledge and skill in the art with respect to antibody structure and function at the time of the invention and the guidance in the specification clearly the skilled artisan would be apprised of antibody regions that participate in binding to LDL or oxLDL.

Second, as discussed above making variant antibodies and fragments (*e.g.*, Fv, Fab, Fab', F(ab')<sub>2</sub>, etc.) was known in the art and routine at the time of the invention, and routine assays for identifying antibodies that bind to LDL or oxLDL are disclosed in the specification (see, *e.g.*, page 14, second paragraph, through page 15). Methods of identifying antibodies that bind to a given antigen without undue experimentation were also known in the art at the time of the invention. Thus, in view of the guidance in the specification and the high level of knowledge and skill in the art at the time of the invention, one skilled in the art could readily make antibodies and fragments that bind to LDL or oxLDL without undue experimentation. For example, the skilled artisan could simply introduce mutations in a light and/or heavy chain variable region (SEQ ID NOs: 1 or 3) and then verify which antibodies and fragments bind to LDL or oxLDL. Consequently, one skilled in the art would not need to predict in advance the effect of any particular variation on antibody binding in order to make variants and functional fragments.

As an example of how routine the methods of producing variant antibodies and identifying those having binding activity were at the time of the invention, submitted herewith as Exhibit A is Boder *et al.* (Proc. Nat'l Acad. Sci. USA 97:10701 (2000)). The authors of Exhibit A describe directed evolution of scFv fragments, and generation of a large number of Fv sequences with improved binding affinity compared to non-mutagenized antibody. Notably, the authors state “[t]he relative ease with which extremely high affinity has been attained in this study.” (page 10705, first column, last full paragraph) Consequently, in view of the fact that functional variants with improved affinity could be made “with relative ease” at the time of the invention, one of skill in the art clearly would have been able to produce variant antibodies and fragments having at least some detectable binding affinity to LDL or oxLDL without undue experimentation at the time of the invention.

Given the fact that one skilled in the art could make and identify variant antibodies and functional fragments that bind to LDL or oxLDL without undue experimentation, there would be no reason to predict the effect of variations on antibody binding. Again, the Patent Office cannot demand that Applicants demonstrate that the skilled artisan must predict functional variants in order to satisfy enablement under 35 U.S.C. §112, first paragraph. Here, one skilled in the art is not required to predict anything in order to make and use antibodies and fragments that bind to LDL or oxLDL without undue experimentation, as held by the court in *Wands*, and corroborated by Exhibit A.

Furthermore, in terms of the concern about “non-operative” embodiments, the claims require binding to LDL or oxLDL, and Applicants specification need only enable what is claimed. Thus, since non-operative embodiments are not encompassed within the claims, and the specification need not enable subject matter outside the scope of the claims, the existence of possible “non-operative” embodiments is irrelevant to enablement of the claims under 35 U.S.C. §112, first paragraph.

In sum, in view of the guidance in the specification and knowledge in the art at the time of the invention, the skilled artisan could readily produce and identify antibody variants and functional fragments of SEQ ID NO:1 and 3 without undue experimentation. Consequently, claims 27 to 32, 34 to 43 and 48 to 51 are adequately enabled under 35 U.S.C. §112, first paragraph, and Applicants respectfully request withdrawal of the rejection.

II. REJECTIONS UNDER 35 U.S.C. §102

The rejection of claims 27 to 43 and 48 to 51 under 35 U.S.C. §102(b), as allegedly anticipated by EP 1531162A1 (Vollmers et al.) is respectfully traversed. The grounds for rejection are set forth in the Office Action, page 15.

Claim 33 has been cancelled herein without prejudice. Thus, the rejection of claim 33 is moot and will be addressed with respect to amended claims 27 to 32, 34 to 43 and 48 to 51.

As discussed above, a Petition to correct the inventorship of the application under 37 C.F.R. §1.48(a)(2), to list Heinz Peter Vollmers was filed on October 21, 2009. Accordingly, upon grant of the Petition by the Office of Petitions, this application properly claims priority as a U.S. national phase of International application no. PCT/DE2004/002503, filed November 12, 2004. As such, EP 1531162A1, published May 18, 2005, is not available as prior art under 35 U.S.C. §102 against claims 27 to 32, 34 to 43 and 48 to 51.

The rejection of claims 27 to 43 and 48 to 51 under 35 U.S.C. §102(f), allegedly due to Applicants not inventing the claimed subject matter is respectfully traversed. The grounds for rejection are set forth in the Office Action, page 15.

Claim 33 has been cancelled herein without prejudice. Thus, the rejection of claim 33 is moot and will be addressed with respect to amended claims 27 to 32, 34 to 43 and 48 to 51.

As discussed above, a Petition to correct the inventorship of the application under 37 C.F.R. §1.48(a)(2), to list Heinz Peter Vollmers was filed on October 21, 2009. Accordingly, upon grant of the Petition by the Office of Petitions, this U.S. national phase properly claims priority to International application no. PCT/DE2004/002503. Consequently, Applicant invented the claimed subject matter and therefore, the rejection under 35 U.S.C. §102(f) must be withdrawn.

**CONCLUSION**

In summary, for the reasons set forth herein, Applicants maintain that claims 27 to 32, 34 to 43 and 48 to 51 clearly and patentably define the invention, respectfully request that the Examiner reconsider the various grounds set forth in the Office Action, and respectfully request the allowance of the claims which are now pending.

If the Examiner would like to discuss any of the issues raised in the Office Action, Applicant's representative can be reached at (858) 509-4065. Please charge any fees associated with the submission of this paper to Deposit Account Number 033975. The Commissioner for Patents is also authorized to credit any over payments to the above-referenced Deposit Account.

Respectfully submitted,

PILLSBURY WINTHROP SHAW PITTMAN LLP



ROBERT M. BEDGOOD  
Reg. No. 43488  
Tel. No. 858.509.4065  
Fax No. 858 509.4010

Date: October 22, 2009  
12255 El Camino Real, Suite 300  
San Diego, CA 92130-4088  
(619) 234-5000

---

**CERTIFICATION UNDER 37 C.F.R. §§ 1.8 and/or 1.10\***

(When using Express Mail, the Express Mail label number is *mandatory*; Express Mail certification is *optional*.)

I hereby certify that, on the date shown below, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: \_\_\_\_\_

\_\_\_\_\_  
Signature

\_\_\_\_\_  
(type or print name of person certifying)

\* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.



# Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity

Eric T. Boder\*, Katarina S. Midelfort†, and K. Dane Wittrup\*††

Departments of \*Chemical Engineering, and †Biophysics, University of Illinois, Urbana, IL 61801

Communicated by Herman N. Eisen, Massachusetts Institute of Technology, Cambridge, MA, June 27, 2000 (received for review May 16, 2000)

Single-chain antibody mutants have been evolved *in vitro* with antigen-binding equilibrium dissociation constant  $K_d = 48$  fM and slower dissociation kinetics (half-time > 5 days) than those for the streptavidin–biotin complex. These mutants possess the highest monovalent ligand-binding affinity yet reported for an engineered protein by over two orders of magnitude. Optimal kinetic screening of randomly mutagenized libraries of  $10^5$ – $10^7$  yeast surface-displayed antibodies enabled a >1,000-fold decrease in the rate of dissociation after four cycles of affinity mutagenesis and screening. The consensus mutations are generally nonconservative by comparison with naturally occurring mouse Fv sequences and with residues that do not contact the fluorescein antigen in the wild-type complex. The existence of these mutants demonstrates that the antibody Fv architecture is not intrinsically responsible for an antigen-binding affinity ceiling during *in vivo* affinity maturation.

Over 100 antibody therapeutics are currently in clinical trials for cancer, viral, autoimmune, and other diseases (1). High-affinity antigen recognition is at the heart of all such therapies and is generally attained by affinity maturation *in vivo* in the mammalian immune system. It has been observed that, during *in vivo* affinity maturation, the B cell response exhibits an apparent affinity ceiling near  $K_d > 0.1$  nM, because of the inability to discriminate slower dissociation kinetics relative to intrinsic B cell receptor internalization rates (2, 3). Because affinity is a critical variable for therapeutic applications such as antibody tumor targeting (4–7), extensive efforts have been made to generate higher affinity antibodies by directed evolution. The highest antibody affinities reported to date are  $K_d \approx 10$ – $20$  pM (8–10).

Antibody/hapten recognition in the 4-4-20/fluorescein model system used in this study has been characterized extensively by structural (11, 12), thermodynamic (13), kinetic (14), computational (15), spectroscopic (16), and mutagenic (17) means. The 4-4-20 affinity for the fluorescein–biotin (FL-bio) hapten ( $K_d = 0.7 \pm 0.3$  nM in PBS) is near the affinity ceiling of the tertiary immune response. The 4-4-20 scFv antibody fragment can be displayed on the surface of yeast, and mutants with increased affinity can be isolated by flow cytometric cell sorting (18). Herein, we report that optimal kinetic screening of randomly mutagenized libraries of  $10^5$ – $10^7$  yeast surface-displayed 4-4-20 antibodies enabled a >10,000-fold decrease in the rate of dissociation (in PBS) after four cycles of affinity mutagenesis and screening. These *in vitro* evolved single-chain antibody mutants have an antigen-binding equilibrium dissociation constant  $K_d = 48$  fM and slower dissociation kinetics (half-time > 5 days) than those for the streptavidin–biotin complex, representing the highest reported monovalent ligand-binding affinity for an engineered protein by over two orders of magnitude. The existence of these mutants demonstrates that the antibody Fv architecture does not possess an intrinsic affinity ceiling for antigen binding.

## Materials and Methods

**Construction of Randomly Mutated scFv Libraries.** A single point mutant of the 4-4-20 scFv (mutant 4 M1.1) with 3-fold higher affinity was isolated previously from a random library generated

in a mutator *E. coli* strain (18). A random scFv library based on this clone was created by adapting the sexual PCR method of Stemmer (19). The expression cassettes of 4 M1.1 and the unselected mutator strain-generated library were amplified by PCR with T3 and T7 promoter standard primers. An equimolar mixture of amplified 4 M1.1 and library PCR products (approximately 30  $\mu$ g) were fragmented to <200 bp by DNase I, purified by gel-filtration with Centri-Sep columns (Princeton Separations, Princeton), and recombined essentially by following the method of Stemmer (19) replacing *Taq* polymerase with Pfu polymerase and performing 45 cycles of PCR. Final PCR amplification was performed with *Taq* polymerase in the presence of 2.25 mM  $MgCl_2$  and 0.375 mM  $MnCl_2$  to introduce further mutations. Primers for final amplification included sequences of  $\approx 100$  bp 5' and 50 bp 3' flanking the scFv ORF to allow efficient enzymatic digestion. PCR products were purified by agarose gel electrophoresis and electroelution, digested with *NheI* and *XhoI*, gel purified, and ligated into digested pCT302 backbone (18). Ligation reactions were exchanged into distilled water, concentrated with Centricon-30 and Microcon-50 filters (Amicon), and transformed into DH10B Electrocompetent cells (Life Technologies, Grand Island, NY). Transformants were pooled, and aliquots were plated to determine library diversity before amplification and purification of plasmid DNA with the Qiagen (Chatsworth, CA) Maxiprep kit. Library DNA was transformed subsequently into yeast strain EBY100 (11) by using the method of Gietz and coworkers (<http://tto.trends.com>). Transformants were pooled in SD-CAA medium [6.7% (vol/vol) yeast nitrogen base/2% (vol/vol) glucose/5% (vol/vol) casamino acids/100 mM sodium phosphate, pH 6.0], and aliquots were plated to determine library diversity. Subsequent libraries were constructed with similar methods, but these methods began with plasmid DNA recovered from a mixed yeast population screened for improved binders in the prior round and the unselected library from the prior round. PCR-amplified DNA from these sources was mixed at a 9:1 molar ratio before DNase I fragmentation. Incorporation of 10% unselected library DNA and error-prone final PCR amplification allowed introduction of further mutations as well as recombination of selected mutations in the resulting library. Individual libraries ranged from  $3 \times 10^5$  to  $2 \times 10^7$  clones.

**Screening of Yeast-Displayed scFv Libraries.** Yeast cells [ $10^8$  in 2.5 ml of TBS (20 mM Tris base/137 mM sodium chloride, pH 7.6)] displaying mutagenized 4-4-20 scFvs were first incubated with 1  $\mu$ M FL-bio to saturate surface binding, washed, and then incubated in 1  $\mu$ M 5-aminofluorescein competitor for a fixed period at 25°C. Competition times were calculated from a mathematical model (20). Labeling with streptavidin-R-

Abbreviations: FL-bio, fluorescein–biotin; LSB, low salt buffer.

See commentary on page 10679.

†To whom reprint requests should be addressed. E-mail: [wittrup@mit.edu](mailto:wittrup@mit.edu)

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Article published online before print: *Proc. Natl. Acad. Sci. USA*, 10.1073/pnas.170297297.  
Article and publication date are at [www.pnas.org/cgi/doi/10.1073/pnas.170297297](http://www.pnas.org/cgi/doi/10.1073/pnas.170297297)


phycoerythrin after competition allowed isolation by flow cytometric sorting of those cells retaining the highest levels of bound FL-bio. Cells were costained with 12CA5 mAb (Roche Molecular Biochemicals) to normalize for cell-to-cell variation in expression level as described (18). Cells were sorted with gate settings determined by using a mathematical analysis (20); four rounds of sorting and regrowth were performed to isolate highly enriched ( $\approx 80\%$ ) populations of improved mutants.

**Kinetic and Sequence Analysis of Isolated Clones.** Individual clones chosen at random were assayed for dissociation rate constants ( $k_{\text{diss}}$ ). Cells were saturated with FL-bio ( $1.0 \mu\text{M}$ ; room temperature; 30 min), washed, labeled with streptavidin-R-phycoerythrin [1:100 streptavidin-phycoerythrin (PharMingen); 30 min on ice], and incubated at  $25^\circ\text{C}$  with at least a 100-fold molar excess of 5-aminofluorescein ( $10 \mu\text{M}$  vs.  $\approx 1 \text{ nM}$  surface-displayed antibody in the reaction). Aliquots were removed and analyzed by flow cytometry at various times; dissociation rate constants were determined by fitting fluorescence data to a first-order kinetic model. Plasmid DNA was recovered from yeast cells by glass bead lysis and phenol:chloroform extraction (21), followed by purification with the Wizard DNA Cleanup kit (Promega) and transformation into competent DH5 $\alpha$ , DH0B, or XL1-Blue cells. scFv ORF sequences were determined by the University of Illinois Biotechnology Center by dideoxy terminator sequencing with an ABI Prism 377. Sequenced clones were chosen based on differing values of  $k_{\text{diss}}$  to avoid sequencing multiple isogenic clones.

**Fluorescence Quenching of Antigen by Soluble scFv Protein.** scFvs were subcloned and expressed solubly in *Saccharomyces cerevisiae* under conditions as described (22). Protein was recovered from raw culture supernatants by affinity chromatography with FITC-coupled BSA. scFv-containing fractions were purified further by FPLC on a Hi-TrapQ anion exchange column (Amersham Pharmacia). Protein concentration, binding constants, and maximal fluorescence quenching constants were determined by direct titration with FL-bio in an SLM Aminco SPF500 spectrofluorometer. Excitation wavelength was 492 nm, and emission was collected at 510 nm; all experiments were conducted in quartz cuvettes thermostated to  $25^\circ\text{C}$ . Dissociation rate constants were measured by addition of a 500-fold molar excess of 5-aminofluorescein (nonfluorescent competitor) at time 0 to an equilibrated mixture of scFv and FL-bio in PBS (150 mM NaCl/10 mM sodium phosphate buffer, pH 8) or low salt buffer (LSB; 1 mM sodium phosphate, pH 8). Association rate constants were determined by injection of FL-bio into equilibrated scFv samples and fitting quenching data to a model with  $k_{\text{diss}}$  values determined from competitive dissociation experiments. Control experiments lacking 4 M5.3 scFv, FL-bio, or 5-aminofluorescein were performed in parallel to ensure the absence of artifacts from adsorption, evaporation, photobleaching, or other processes over the course of the experiment.

## Results and Discussion

The complete 4-4-20 scFv ORF was mutagenized by error-prone DNA shuffling (19). Fluorescently labeled clones exhibiting slowed antibody-hapten dissociation kinetic constants were identified and isolated by flow cytometry with optimal screening and sorting conditions calculated from a mathematical model (20). Up to 20 improved clones were selected randomly for individual measurement of the dissociation rate constant  $k_{\text{diss}}$ , and 10 improved clones exhibiting the widest range of  $k_{\text{diss}}$  values were selected for further analysis and are represented in Fig. 1A. The complete collection of isolated mutants was then recombined by modified DNA shuffling, together with further error-prone PCR mutagenesis. This cycle of mutagenesis and screening was repeated three times, resulting in mutant scFvs with



**Fig. 1.** Dissociation kinetics of mutant scFv at  $25^\circ\text{C}$ . (A) Yeast displaying mutant scFv isolated from a random library was assayed for antigen dissociation rate. The 4-4-20 and V<sub>H</sub>S95A values were calculated from fluorescence quenching data with soluble scFvs. Dissociation rates for barnase/barstar (45), streptavidin/biotin (46), avidin/biotin (46), and trypsin/bovine pancreatic trypsin inhibitor (BPTI) (47) are indicated for comparison. (B) Dissociation kinetics of purified, soluble 4 M5.3 and 4-4-20 scFvs were assayed by fluorescence quenching. Triplicate traces for 4-4-20 scFv in PBS (150 mM NaCl/10 mM sodium phosphate buffer, pH 8) are shown, and 12 independent replicates are shown for 4 M5.3 in PBS or LSB.  $\tau_{1/2}$ , half-time for dissociation.

Table 1. Binding and dissociation rate constants for soluble scFvs

scFv	Buffer	$k_{\text{ass}} (\times 10^{-7} \text{ M}^{-1} \text{ s}^{-1})$	$k_{\text{diss}} (\times 10^6 \text{ s}^{-1})$	$K_d$ , fM	
				$k_{\text{diss}}/k_{\text{ass}}$	Direct titration
4-4-20	PBS	$8.0 \pm 3.5$	$25,100 \pm 500$	310,000	$700,000 \pm 300,000$
	LSB	$41.0 \pm 8.0$	$4,270 \pm 100$	10,000	ND
4 M5.3	PBS	$0.6 \pm 0.03$	$1.6 \pm 0.3$	270	ND
	LSB	$2.9 \pm 0.9$	$1.4 \pm 0.4$	48	ND

ND, not determined.

dissociation rate constants over four orders of magnitude slower than the  $k_{\text{diss}}$  of the 4-4-20 scFv (Fig. 1). As a basis for comparison, the dissociation rates for other high-affinity protein–ligand complexes are also shown in Fig. 1. The half-time for dissociation of the 4 M5.3 mutant is over 5 days, such that optimal screening of a fifth library would require kinetic competition times longer than 3 weeks (20) for each of four subsequent enrichment sorting steps.

A clone from the fourth library screen (4 M5.3) was solubly expressed, and the association and dissociation constants were measured in solution (Table 1; Fig. 1B). These kinetic values are in quantitative agreement with those measured on the cell

surface (Fig. 1A). Electrostatic steering of fluorescein into the binding pocket (23, 24) is evidenced by the salt dependence of  $k_{\text{ass}}$ . The association rate constant of 4 M5.3 is  $\approx 14$ -fold lower than that of 4-4-20 scFv in both PBS and LSB. This decrease somewhat offsets the 16,000-fold improvement in  $k_{\text{diss}}$  (3,000-fold in LSB), resulting in  $K_d = 270$  fM in PBS and  $K_d = 48$  fM in LSB. To our knowledge, the 4 M5.3/FL-bio interaction is the highest affinity noncovalent protein–ligand complex yet engineered.


Sequences were obtained of each of the mutants represented in Fig. 1, and mutated residues are shown in Table 2. With the exception of 4 M4.15, 16, and 19 (which are identical isolates),

Table 2. Mutations in selected scFvs

Kabat #	WT	4M2.2	4M2.3	4M2.4	4M2.5	4M2.6	4M2.7	4M2.8	4M2.9	4M2.10	4M3.1	4M3.2	4M3.3	4M3.4	4M3.6	4M3.7	4M3.8	4M3.10	4M3.11	4M3.12	4M4.9	4M4.4	4M4.5	4M4.10	4M4.12	4M4.13	4M4.14	4M4.15	4M4.16	4M4.19	4M5.2	4M5.3	4M5.4	4M5.5	4M5.7	4M5.9	4M5.13	4M5.15	4M5.16	4M5.20	CDR	
1	D																																									1
5	T																																									5
17	D																																									17
19	A																																									19
24	R																																									24
27a	S																																									27a
27c	V																																									27c
29	G																																									29
39	K																																									39
50	K																																									50
55	F																																									55
56	S																																									56
70	D																																									70
76	S																																									76
77	R																																									77
79	E																																									79
84	G																																									84
100	G																																									100
107	K																																									107
1	E																																									1
5	D																																									5
12	V																																									12
16	R																																									16
17	P																																									17
19	K																																									19
24	A																																									24
30	S																																									30
31	D																																									31
49	V																																									49
51	I																																									51
55	Y																																									

Red = previously identified in 4 clones

Blue = isolate in previous study from case




**Fig. 2.** Natural conservation of mutated 4-4-20 residues. Comparison of occurrence frequencies in mouse  $V_H$  and  $V_L$   $\kappa$  genes of wild-type (abscissa) and mutation (ordinate) amino acid identities are shown. Frequencies were calculated at mutated sequence positions from statistics in the Kabat database (25).

all mutant clones are distinct. In each round, at least one mutation was found in a majority of the clones (henceforth termed “consensus” mutations). No consensus mutations were identified in the linker or epitope tag regions; thus, these are not represented in Table 2 for conciseness.

Consensus mutations accumulate in each round; once fixed in an early round, they generally are present in subsequent rounds. It is noteworthy that particular consensus mutations dominate the screened population at each round. It is not possible to ascertain from the available information whether mutations added in subsequent rounds were introduced by recombination of preexisting mutations or *de novo* mutagenesis during error-prone PCR and DNA shuffling. Of 10 consensus mutations after the fourth round of screening, 9 of 10 are in the  $V_H$  domain, and 6 of 10 are in CDR loops. The relative paucity of mutations in the  $V_L$  domain is striking, with 6-fold, 7-fold, 7-fold, and 4-fold excess mutations in  $V_H$  relative to  $V_L$  in each of the four rounds, respectively. Comparison of frequency in the Kabat database (25) for consensus mutations vs. 4-4-20 wild-type residues indicates that 9 of 10 consensus changes are to rare amino acids at those positions, as shown in Fig. 2. Most striking in this regard is the  $V_H103$  mutation (fixed in the mutant population in round 1), which alters the nearly invariant  $V_H103$  tryptophan residue (99.3% of mouse  $V_H$  sequences in the Kabat database). Of the 10 consensus mutant substitutions, 9 occur in fewer than 10% of known mouse antibody sequences, by comparison to only one such nonconserved residue at these sites in the wild-type 4-4-20 sequence. Thus, this *in vitro* directed evolution approach generally sampled areas of antibody sequence space infrequently accessed by the *in vivo* process, perhaps because of constraints arising from the mechanism of somatic hypermutation.

The locations of consensus mutations are identified on the 4-4-20 Fab crystal structure shown in Fig. 3. The consensus mutations cluster strikingly around  $V_H$  CDR3; it has been argued previously that the  $V_H$  CDR3 loop exerts the greatest influence on antigen-binding specificity (26–28). The 4-4-20 CDR loops can be grafted onto a different scFv framework without loss of affinity (29), indicating that fluorescein recognition is dominated by the CDR loops. In fact, 9 of the 10



**Fig. 3.** Sites of consensus mutations in the 4-4-20 Fv. Backbone structure of the first 118 heavy-chain residues (gray) and the first 112 light-chain residues (blue) are shown. Fluorescein ligand (green) and mutated residues are depicted by space-filling models. Mutation sites are color-coded by distance from the binding site: first-shell residues are magenta; second-shell residues are yellow; third-shell residues are cyan; and fourth-shell residues are white. Residues in the first shell were defined as those with one or more atoms directly contacting ligand; second-shell residues were defined as those with one or more atoms directly contacting any residue in the first shell; third- and fourth-shell residues contact second- and third-shell residues, respectively. Definitions of contact were interatomic distances (in Å) equal to or less than 4.1 C–C, 3.3 O–O, 3.4 N–N and N–O, 3.8 C–N, and 3.7 C–O (48). Atomic coordinates were from the high-resolution crystal structure of Whitlow, et al. (ref. 11; PDB ID code 1FLR).

consensus mutations identified in the present work are located at 4-4-20 residues that were present in the loop-grafted 4D5Flu hybrid protein, indicating that they lie within the portion of the scFv largely responsible for binding specificity. Of particular interest is the  $V_L$ F55V mutation enriched in the fourth round of this study, which was also identified independently as one of two mutations that together improved the stability of 4D5Flu by 4 kcal/mol, with an unexpected 20-fold increase in affinity (30).

Only 1 of 10 4 M5.3 consensus mutations is in a fluorescein-contact residue; 3 are in the second shell; 3 are in the third shell; and 2 are in the fourth shell (Fig. 3).  $V_H$ 87 is on the scFv face opposite the fluorescein-binding pocket. This spatial distribution generally supports the observation that further affinity maturation of antibodies with affinity in the low nanomolar range occurs most effectively via changes in “vernier” or second-sphere residues (31, 32) rather than contact residues (33). In addition, 4 of 10 consensus mutations occur at  $V_H$ – $V_L$  interfacial sites, suggesting that improved stability and/or orientation of the  $V_H$ – $V_L$  domain pairing may be important in affinity improvement for the scFv.

A molecular dynamics comparison of liganded and unliganded 4-4-20 demonstrates a significant increase in interresidue correlated motions on fluorescein binding, particularly in the  $V_H$  domain (15). The 4-4-20  $V_H$  domain possesses generally larger temperature factors than the  $V_L$  domain (11), indicating greater flexibility. Of the 10 consensus mutations, 9 lie within  $V_H$ , which could be consistent with the binding site preorganization mechanism for affinity improvement proposed previously for antibody affinity maturation from the germ-line sequence (34). Dissection of the thermodynamic, kinetic, and structural mechanisms by which the mutations in 4 M5.3 increase binding free energy by 3–4 kcal/mol should contribute to an improved understanding of protein recognition. Information gleaned from

these gain-of-function mutations would complement loss-of-function mutational studies of strong protein–ligand interactions such as streptavidin–biotin (35).

The majority of current antibody engineering strategies focus mutagenesis on the antibody CDR loops (e.g., refs. 8, 10, 36, and 37), an approach that would not identify 4 of the 10 consensus mutations from this study. In fact, the first consensus mutation to become fixed ( $V_HW103L$ ) occurred at a highly conserved framework position removed from the binding site; the possibility that 1 or more subsequently selected mutations depended on the context of the  $V_H103$  mutation must be considered. The experimentally simpler strategy of error-prone PCR of the whole scFv gene was therefore arguably more effective given these results. Concerns regarding potential immunogenicity of framework mutations in a therapeutic antibody might be addressed by judicious choice of buried residues from among the selected mutations.

The relative ease with which extremely high affinity has been attained in this study might be attributed to (i) quantitatively optimized screening methodology and (ii) minimization of expression bias by use of a eukaryotic expression host. In the first instance, labeling for optimal discrimination of improved clones (20) and reduced stochastic variation in dissociation kinetics because of assay of  $10^4$ – $10^5$  scFv molecules per yeast cell enable fine discrimination of affinity (reproducibility of  $\pm 10\%$  in  $k_{\text{diss}}$  assayed by flow cytometry for yeast-displayed scFvs and  $\pm 30\%$  for  $K_d$ ; ref. 38). In the second instance, yeast's secretory biosyn-

thetic apparatus effectively folds and displays or secretes (22) the 4-4-20 scFv, a molecule that forms inclusion bodies and is 98% insoluble when expressed in the periplasm of wild-type *E. coli* (39). Thus, a greater proportion of protein shape space will be sampled by yeast display because of elimination of prokaryotic expression biases against scFvs such as 4-4-20.

Generation of antibodies that bind essentially irreversibly relative to the relevant physiological time scale could improve efficacy for cancer immunotherapy with noninternalizing tumor-associated antigens (4–7) and passive immunization against viral and microbial pathogens (40–43). The mutagenesis and screening methodology described herein has also been applied successfully to an antibody against hen egg lysozyme (data not shown) and an antibody against the T cell receptor (44). Beyond the implications of the general capability to engineer femtomolar affinity antibodies, more specifically, a molecule such as 4 M5.3 that binds and quenches fluorescein with an affinity similar to that of streptavidin–biotin may enable interesting approaches in analytical biochemistry when combined with the array of available fluorescence-detection methodologies.

The 4-4-20 scFv was obtained from D. M. Kranz, who also provided helpful comments on the manuscript. We thank G. Durack for assistance optimizing cell-sorting instrumentation. Funding was provided by the Whitaker Foundation and National Institutes of Health Grant GM55767.

- Halim, N. S. (2000) *The Scientist* **14**, 16–17.
- Batista, F. D. & Neuberger, M. S. (1998) *Immunity* **8**, 751–759.
- Foot, J. & Eisen, H. N. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 1254–1256.
- Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D. & Weiner, L. M. (1998) *Cancer Res.* **58**, 485–490.
- Colcher, D., Pavlinkova, G., Beresford, G., Booth, B. J., Choudhury, A. & Batra, S. K. (1998) *Q. J. Nucl. Med.* **42**, 225–241.
- Roovers, R. C., Henderix, P., Helfrich, W., van der Linden, E., Reurs, A., de Bruine, A. P., Arends, J. W., de Leij, L. & Hoogenboom, H. R. (1998) *Br. J. Cancer* **78**, 1407–1416.
- Jackson, H., Bacon, L., Pedley, R. B., Derbyshire, E., Field, A., Osbourn, J. & Allen, D. (1998) *Br. J. Cancer* **78**, 181–188.
- Schier, R., Bye, J., Apell, G., McCall, A., Adams, G. P., Malmqvist, M., Weiner, L. M. & Marks, J. D. (1996) *J. Mol. Biol.* **255**, 28–43.
- Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M. & Lowman, H. B. (1999) *J. Mol. Biol.* **293**, 865–881.
- Yang, W.-P., Green, K., Pinz-Sweeney, S., Briones, A. T., Burton, D. R. & Barbas, C. F. I. (1995) *J. Mol. Biol.* **254**, 392–403.
- Whitlow, M., Howard, A. J., Wood, J. F., Voss, E. W., Jr., & Hardman, K. D. (1995) *Protein Eng.* **8**, 749–761.
- Herron, J. N., Terry, A. H., Johnston, S., He, X. M., Guddat, L. W., Voss, E. W., Jr., & Edmundson, A. B. (1994) *Biophys. J.* **67**, 2167–2183.
- Herron, J. N., Kranz, D. M., Jameson, D. M. & Voss, E. W., Jr. (1986) *Biochemistry* **25**, 4602–4609.
- Kranz, D. M., Herron, J. N. & Voss, E. W., Jr. (1982) *J. Biol. Chem.* **257**, 6987–6995.
- Lim, K. & Herron, J. N. (1995) *Biochemistry* **34**, 6962–6974.
- Lim, K., Jameson, D. M., Gentry, C. A. & Herron, J. N. (1995) *Biochemistry* **34**, 6975–6984.
- Denzin, L. K., Gulliver, G. A. & Voss, E. W., Jr. (1993) *Mol. Immunol.* **30**, 1331–1345.
- Boder, E. T. & Wittrup, K. D. (1997) *Nat. Biotechnol.* **15**, 553–557.
- Stemmer, W. P. (1994) *Nature (London)* **370**, 389–391.
- Boder, E. T. & Wittrup, K. D. (1998) *Biotechnol. Progr.* **14**, 55–62.
- Ward, A. C. (1990) *Nucleic Acids Res.* **18**, 5319.
- Shusta, E. V., Raines, R. T., Pluckthun, A. & Wittrup, K. D. (1998) *Nat. Biotechnol.* **16**, 773–777.
- Omelyanenko, V. G., Jiskoot, W. & Herron, J. N. (1993) *Biochemistry* **32**, 10423–10429.
- Leckband, D. E., Kuhl, T., Wang, H. K., Herron, J., Muller, W. & Ringsdorf, H. (1995) *Biochemistry* **34**, 11467–11478.
- Johnson, G., Wu, T. T. & Kabat, E. A. (1996) in *Immunochromatography and Molecular Immunology*, Weir's Handbook of Experimental Immunology, eds. Herzenberg, L. A., Weir, W. M., Herzenberg, L. A. & Blackwell, C. (Blackwell Science, Cambridge, MA), Vol. 1, pp. 6.1–6.21.
- Davis, M. M., Lyons, D. S., Altman, J. D., McHeyzer-Williams, M., Hampl, J., Boniface, J. J. & Chien, Y. (1997) *Ciba Found. Symp.* **204**, 94–100.
- VanDyk, L. & Meek, K. (1992) *Int. Rev. Immunol.* **8**, 123–133.
- Kabat, E. A. & Wu, T. T. (1991) *J. Immunol.* **147**, 1709–1719.
- Jung, S. & Pluckthun, A. (1997) *Protein Eng.* **10**, 959–966.
- Jung, S., Honegger, A. & Pluckthun, A. (1999) *J. Mol. Biol.* **294**, 163–180.
- Arkin, M. R. & Wells, J. A. (1998) *J. Mol. Biol.* **284**, 1083–1094.
- Foot, J. & Winter, G. (1992) *J. Mol. Biol.* **224**, 487–499.
- Burks, E. A., Chen, G., Georgiou, G. & Iverson, B. L. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 412–417.
- Wedemayer, G. J., Patten, P. A., Wang, L. H., Schultz, P. G. & Stevens, R. C. (1997) *Science* **276**, 1665–1669.
- Freitag, S., Chu, V., Penzotti, J. E., Klumb, L. A., To, R., Hyre, D., Le Trong, I., Lybrand, T. P., Stenkamp, R. E. & Stayton, P. S. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 8384–8389.
- Wu, H., Beuerlein, G., Nie, Y., Smith, H., Lee, B. A., Hensler, M., Huse, W. D. & Watkins, J. D. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 6037–6042.
- Daugherty, P. S., Chen, G., Olsen, M. J., Iverson, B. L. & Georgiou, G. (1998) *Protein Eng.* **11**, 825–832.
- VanAntwerp, J. J. & Wittrup, K. D. (2000) *Biotechnol. Progr.* **16**, 31–37.
- Nieba, L., Honegger, A., Krebber, C. & Pluckthun, A. (1997) *Protein Eng.* **10**, 435–444.
- Bachmann, M. F., Kalinke, U., Althage, A., Freer, G., Burkhart, C., Roost, H., Aguet, M., Hengartner, H. & Zinkernagel, R. M. (1997) *Science* **276**, 2024–2027.
- Lamarre, A. & Talbot, P. J. (1995) *J. Immunol.* **154**, 3975–3984.
- Gauduin, M. C., Parren, P. W., Weir, R., Barbas, C. F., Burton, D. R. & Koup, R. A. (1997) *Nat. Med.* **3**, 1389–1393.
- Ma, J. K., Hikmat, B. Y., Wycoff, K., Vine, N. D., Chargelegue, D., Yu, L., Hein, M. B. & Lehner, T. (1998) *Nat. Med.* **4**, 601–606.
- Kieck, M. C., Cho, B. K., Boder, E. T., Kranz, D. M. & Wittrup, K. D. (1997) *Protein Eng.* **10**, 1303–1310.
- Schreiber, G. & Fersht, A. R. (1993) *Biochemistry* **32**, 5145–5150.
- Piran, U. & Riordan, W. J. (1990) *J. Immunol. Methods* **133**, 141–143.
- Fritz, H. & Wunderer, G. (1983) *Arzneimittelforschung* **33**, 479–494.
- Braden, B. C., Goldman, E. R., Mariuzza, R. A. & Poljak, R. J. (1998) *Immunol. Rev.* **163**, 45–57.